These findings provide a foundation for integrating CD73 and VEGF expression into clinical decision-making, helping clinicians identify patients who may benefit from targeted therapies and guiding personalized treatment strategies for salivary gland carcinoma. The gene discussed is NT5E; the disease is salivary gland carcinoma.